Skip to main content
    K

    Kiniksa Pharmaceuticals Ltd (KNSA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $94.23
    -2.10 (-2.18%)

    Market Cap: $7.57B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kiniksa Pharmaceuticals Ltd (KNSA) Earnings: Report Dates and Results

    Updated Oct 27, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Kiniksa Pharmaceuticals (KNSA) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Kiniksa Pharmaceuticals reported EPS of $0.56, above the $0.32 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(17/34)
    Avg Surprise
    -27.96%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.29
    Range$0.16 - $0.43
    9 analysts
    Revenue Consensus
    $312.68M
    Range$296.84M - $330.33M
    9 analysts
    Reports Apr 26, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.44
    Range$0.29 - $0.55
    4 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.36+22.2%
    60d ago$0.36+22.2%
    30d ago$0.36+22.2%
    7d ago$0.36+22.2%
    Current$0.44
    Revenue Consensus
    $313.78M
    Range$310.00M - $320.90M
    5 analysts

    Next Report

    KNSA has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 70.6% above the $0.17 reported for the quarter ended Dec 31, 2025.

    KNSA Earnings Call

    The latest KNSA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 34 quarters below that had an estimate, KNSA beat 17, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $285.97M, up 58.1% from $180.85M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.56$0.32$0.27 - $0.37+75.00%Beat+143.5%42 up, 2 downOct 27, 2026$285.97M
    Jun 30, 2026$0.30$0.30$0.27 - $0.300.00%In line+30.4%40 up, 0 downJul 28, 2026$243.60M
    Mar 31, 2026$0.27$0.16$0.13 - $0.20+68.75%Beat+145.5%30 up, 1 downApr 28, 2026$214.27M
    Dec 31, 2025$0.17$0.40$0.29 - $0.53-57.50%MissN/A50 up, 0 downFeb 24, 2026$202.13M
    Sep 30, 2025$0.23$0.37$0.26 - $0.57-37.84%MissN/A51 up, 1 downOct 28, 2025$180.85M
    Jun 30, 2025$0.23$0.26$0.16 - $0.37-11.54%MissN/A50 up, 1 downJul 29, 2025$156.80M
    Mar 31, 2025$0.11$0.28-$0.14 - $0.71-60.71%MissN/A40 up, 0 downApr 29, 2025$137.78M
    Dec 31, 2024-$0.12$0.02-$0.13 - $0.33-700.00%Miss-134.3%30 up, 0 downFeb 25, 2025$122.54M
    Sep 30, 2024-$0.18$0.07-$0.06 - $0.18-357.14%MissN/A51 up, 0 downOct 29, 2024$112.21M
    Jun 30, 2024-$0.06$0.01N/A-700.00%Miss-128.6%40 up, 0 downJul 23, 2024$108.63M
    Mar 31, 2024-$0.25-$0.08N/A-212.50%MissN/A30 up, 0 downApr 23, 2024$79.86M
    Dec 31, 2023$0.35-$0.14-$0.23 - -$0.04+350.00%Beat+483.3%40 up, 0 downFeb 28, 2024$83.39M
    Sep 30, 2023-$0.20-$0.16-$0.22 - -$0.11-25.00%Miss-106.3%40 up, 0 downOct 31, 2023$67.05M
    Jun 30, 2023$0.21-$0.13-$0.20 - -$0.12+261.54%BeatN/A40 up, 0 downJul 25, 2023$71.47M
    Mar 31, 2023-$0.18-$0.21-$0.28 - -$0.12+14.29%BeatN/A40 up, 0 downMay 2, 2023$48.34M
    Dec 31, 2022$0.06-$0.14N/A+142.86%BeatN/A40 up, 0 downFeb 28, 2023$61.88M
    Sep 30, 2022$3.18$0.83-$0.34 - $0.87+283.13%BeatN/A40 up, 0 downNov 1, 2022$99.14M
    Jun 30, 2022-$0.29-$0.39N/A+25.64%BeatN/A40 up, 0 downAug 3, 2022$26.97M
    Mar 31, 2022-$0.36-$0.26N/A-38.46%MissN/A31 up, 0 downMay 3, 2022$32.19M
    Dec 31, 2021-$0.53-$0.42-$0.47 - -$0.33-26.19%MissN/A4N/AFeb 22, 2022$18.75M
    Sep 30, 2021-$0.44-$0.63-$0.70 - -$0.62+30.16%BeatN/A4N/ANov 1, 2021$12.10M
    Jun 30, 2021-$0.61-$0.77-$1.16 - -$0.63+20.78%BeatN/A4N/AAug 3, 2021$7.70M
    Mar 31, 2021-$0.72-$0.63-$0.92 - -$0.35-14.29%MissN/A4N/AMay 4, 2021N/A
    Dec 31, 2020-$0.79-$0.62-$0.70 - -$0.55-27.42%MissN/A4N/AFeb 23, 2021N/A
    Sep 30, 2020-$0.66-$0.59-$0.76 - -$0.49-11.86%MissN/A4N/ANov 5, 2020N/A
    Jun 30, 2020-$0.65-$0.58-$0.76 - -$0.50-12.07%MissN/A5N/AJul 30, 2020N/A
    Mar 31, 2020-$0.48-$0.62-$0.74 - -$0.58+22.58%BeatN/A5N/AApr 28, 2020N/A
    Dec 31, 2019-$0.58-$0.62-$0.72 - -$0.54+6.45%BeatN/A4N/AFeb 26, 2020N/A
    Sep 30, 2019-$0.49-$0.70-$0.75 - -$0.66+30.00%BeatN/A4N/AOct 28, 2019N/A
    Jun 30, 2019-$0.68-$0.76-$0.78 - -$0.65+10.53%BeatN/A4N/AAug 12, 2019N/A
    Mar 31, 2019-$0.73-$0.79-$0.89 - -$0.60+7.59%BeatN/A5N/AMay 2, 2019N/A
    Dec 31, 2018-$0.88-$0.75-$0.85 - -$0.62-17.33%Miss-4500.0%4N/AMar 7, 2019N/A
    Sep 30, 2018-$0.51-$0.53-$0.66 - -$0.45+3.77%BeatN/A4N/ANov 1, 2018N/A
    Jun 30, 2018-$0.47-$0.50-$0.59 - -$0.23+6.00%BeatN/A4N/AAug 6, 2018N/A
    Mar 31, 2018-$0.10N/AN/AN/AN/AN/AN/AN/AMay 24, 2018N/A
    Dec 31, 2017$0.02N/AN/AN/AN/AN/AN/AN/AMar 30, 2018N/A
    Last 36 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.74, a profit after a loss of $0.61 per share the year before. It was $0.02 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.74N/A
    Dec 31, 2024-$0.61-438.9%
    Dec 31, 2023$0.18-93.1%
    Dec 31, 2022$2.59N/A
    Dec 31, 2021-$2.30N/A
    Dec 31, 2020-$2.58N/A
    Dec 31, 2019-$2.48N/A
    Dec 31, 2018-$1.96-9900.0%
    Dec 31, 2017$0.02N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,48211
    2026Q2Jun 30, 20264,95912
    2026Q1Mar 31, 20264,58014
    2025Q4Dec 31, 20253,88311
    2025Q3Sep 30, 20255,15213
    2025Q2Jun 30, 20254,54712
    2025Q1Mar 31, 20254,36212
    2024Q4Dec 31, 20243,1719

    2026Q3 Earnings Call

    Opening remarks

    Jonathan Kirshenbaum Investor Relations Thank you, operator. Good morning, everyone, and welcome to the Kiniksa Pharmaceuticals Third Quarter 2026 Earnings Call. A press release highlighting our financial results and recent portfolio execution can be found on our website under the Investors section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. From there, Ross Moat, our Chief Operating Officer, will provide an update on ARCALYST commercial execution. After that, Mark Ragosa, our Chief Financial Officer, will review our third quarter 2026 financial results. Finally, Sanj will return at the end of the call to share closing remarks and kick off the Q&A session, for which John Paolini, Kiniksa's Chief Medical Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from such statements. A review of these statements and risk factors can be found on this slide, as well as under the caption Risk Factors contained in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I'll turn it over to Sanj.

    Sanj K. Patel CEO Thanks, Jonathan, and good morning or good afternoon, everyone. Over the last 10, 11 years, we've built this company through multiple stages of growth, and today, I'm as excited as ever about what the team and I can accomplish together in the years ahead. Kiniksa continues to build a leading IL-1 alpha and beta inhibition franchise driven by the commercialization of ARCALYST in recurrent pericarditis, as well as our progress with KPL-387 and KPL-1161. This morning, we announced via a press release that we've raised our full-year revenue guidance to between $1.045 billion and $1.050 billion. We continue to see robust growth with ARCALYST in recurrent pericarditis, driven by strong execution and strategic investments across the business. On the clinical side, we're excited about the progress of KPL-387 and KPL-1161. The pivotal phase III study with KPL-387 continues to enroll and dose patients. We announced today that we expect data from this trial in the second half of 2027. The team and I are really looking forward to potentially launching this drug in the 2028, 2029 timeframe. In addition to providing an important treatment option for patients with recurrent pericarditis, we believe KPL-387 could help grow the market by enabling a once-monthly subQ dosing. We are also on track to have KPL-1161, our quarterly IL-1 alpha and beta inhibitor, in a phase I clinical trial by the end of this year.

    Frequently Asked Questions About KNSA

    When is Kiniksa Pharmaceuticals's next earnings date?

    Kiniksa Pharmaceuticals's next earnings report is expected for Feb 22, 2027.

    Did KNSA beat earnings estimates last quarter?

    Yes. Kiniksa Pharmaceuticals reported EPS of $0.56 for the quarter ended Sep 30, 2026, above the $0.32 estimate, a 75.00% surprise.

    What EPS do analysts expect from KNSA next quarter?

    The consensus EPS estimate for Kiniksa Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.29 from 9 analysts, with estimates from $0.16 to $0.43.

    How often does KNSA beat earnings estimates?

    Kiniksa Pharmaceuticals beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -90.48%.